title: Treatment of muscle invasive bladder cancer. Is there a role for neoadjuvant chemotherapy?
abstract: OBJECTIVE
  Because 5-year survival with advanced bladder cancer is still poor, the search for optimal treatment continues as dose the necessity of clarifying goals of treatment.
  
  
  METHODS
  We compared the outcome of 3 different but widely accepted treatment protocols for bladder cancer in order to find which, if any, was superior, with particular emphasis upon the performance of the newest treatment, neoadjuvant chemotherapy. Data on 224 bladder patients treated at our institution (1975 to 1991) with 1 of the 3 protocols was analyzed. Those protocols were: 1. radiotherapy > 60 Gy (143 patients); 2. low dose radiotherapy followed by cystectomy (25 patients); 3. chemotherapy followed by either definitive radiotherapy or surgery (56 patients). Because the latter group was also a chronologically newer group with a shorter possible follow-up, we compared all treatments on the basis of 2-year survival, using Kaplan-Meier life tables. We briefly reviewed those modalities which are bladder-sparing because of the significance to quality of life of this factor.
  
  
  RESULTS
  Two-year survival figures for the patients were: 63% for those who received only radiotherapy; 72% for those undergoing cystectomy: 68% for the group to whom neoadjuvant chemotherapy was administered. The differences were not statistically significant. However, 23% of those patients treated neoadjuvantly were alive with intact bladders at 2 years.
  
  
  CONCLUSIONS
  These results do not suggest that a superior survival advantage is associated with any of these 3 protocols and neoadjuvant chemotherapy, in particular, cannot be seen as conferring a new and important survival advantage. However, neoadjuvant chemotherapy followed by radiotherapy does permit bladder conservation and, given that life span will often be reduced, the importance of helping to keep the remainder of the patient's life as comfortable as possible, can hardly be overestimated.
authors.affiliation: Northern Israel Oncology Center, Rambam Medical Center, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.
authors.forename: A
authors.initials: A
authors.lastname: Kuten
authors.forename: M
authors.initials: M
authors.lastname: Baz
authors.forename: R
authors.initials: R
authors.lastname: Rubinov
authors.forename: J
authors.initials: J
authors.lastname: Dale
authors.forename: N
authors.initials: N
authors.lastname: Haim
authors.forename: E
authors.initials: E
authors.lastname: Robinson
authors.forename: Y
authors.initials: Y
authors.lastname: Cohen
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy / Q000706:statistics & numerical data; D015653:Cystectomy; D005260:Female; D006801:Humans; D007557:Israel / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010166:Palliative Care / Q000706:statistics & numerical data; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*